Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Sutent (sunitinib malate)
pCPA File Number:
20751
Negotiation Status:
Concluded with an LOI
Indication(s):
Pancreatic Neuroendocrine Tumors
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
pCODR 10004
pCPA Engagement Letter Issued:
2012-12-01
Negotiation Process Concluded:
2013-08-14